ArticleCardiovascular research2025
YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells.
Article in Cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Epitranscriptomic profiling of VSMC phenotypes reveals uridine modifications linked to post-transcriptional regulation.Biochemistry and biophysics reports · 2026Article
- CD4Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs.Cardiovascular research · 2026Article
- N6-methyladenosine (m6A) post-transcriptional modification regulation of mRNA, an overlooked therapeutic opportunity to leverage mRNA processing in vascular smooth muscle cells.Vascular pharmacology · 2026Review
- A Comprehensive Review of Epigenetic Regulation of Vascular Smooth Muscle Cells During Development and Disease.Biomolecules · 2026Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
aimsRecent genome-wide association study analysis has identified YY1 as a novel locus associated with blood pressure traits; however, whether YY1 directly controls vasoreactivity remains unknown. The principal function of vascular smooth muscle cells (VSMCs) is to contract, which is essential for regulating vascular tone, blood flow, and blood pressure. We hypothesized that YY1, a transcription factor, facilitates vascular function by epigenetically regulating gene expression in VSMCs. METHODS AND
resultsThe effects of VSMC-specific YY1 loss were studied in mice. Lineage tracing, calcium imaging, and wire myography were performed to assess vasoreactivity. Genome-wide analysis through RNA-seq, ChIP-seq, m6A-seq, RNA immunoprecipitation, and transcript stability assays were conducted to evaluate gene expression and regulation. Co-immunoprecipitation was performed to study interactions between YY1 and chromatin regulators. AAV-mediated SM22-specific gene delivery was used to rescue vascular function in vivo. Contractile VSMCs were differentiated from human embryonic stem cells for in vitro experiments. Hypertension was induced in vivo using salt and L-NAME treatments. We demonstrate that vascular contraction and blood pressure are significantly reduced in Myh11CreER;Yy1fl/fl mice. YY1 does not regulate VSMC proliferation, survival, calcium entry, or membrane polarization in homeostasis. Integrative analyses of transcriptomics, epitranscriptomics, and epigenetics identified Mettl3 as a putative downstream target of YY1. Like YY1 loss-of-function, impaired vascular contraction and reduced blood pressure were observed in Myh11CreER;Mettl3fl/fl mice. Mylk2, Tgfb2, and Myh11 were significantly down-regulated after genetic ablation of Yy1 or Mettl3 in VSMCs. Further analysis showed that Mettl3-mediated m6A mRNA methylation stabilizes the transcripts of these genes, possibly through the m6A reader IGF2BP1. AAV-mediated, VSMC-specific Mettl3 gene delivery significantly improved vascular contractility in Yy1-deficient mice, functionally confirming Mettl3 as a direct downstream target of YY1. Mechanistically, YY1 binds to the Mettl3 promoter near regions of H3K4 trimethylation and activates Mettl3 transcription by recruiting Set1A-Wdr82 complex for H3K4me3 deposition. Both Myh11CreER;Yy1fl/fl and Myh11CreER;Mettl3fl/fl mice exhibited delayed onset of hypertension.
conclusionYY1 maintains vascular contraction and regulates blood pressure by stabilizing Mylk2, Tgfb2, and Myh11 transcripts through the activation of Mettl3 transcription in VSMCs. These findings provide novel insights into the epigenetic control of VSMC epitranscriptomes and unravel a new mechanism underlying VSMC-mediated vasoconstriction through the YY1/Mettl3 regulatory axis. Additionally, our results demonstrate a clinically relevant role for the YY1/Mettl3 axis in mitigating hypertension and regulating blood pressure under both normal and hypertensive conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.